Publications by authors named "Lawrence Rubinstein"

Claim this Profile
S
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors.
Geraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, Sarina Piha-Paul, Lawrence Rubinstein

JCO Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models.
Yvonne A Evrard, Sergio Y Alcoser, Michael Mullendore, Li Chen, Chih-Jian Lih, Lawrence V Rubinstein

Front Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, Angela M DeMichele, Richard Piekarz, Lawrence V Rubinstein

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Funda Meric-Bernstam, Michael W Lloyd, Soner Koc, Yvonne A Evrard, Lisa M McShane, Lawrence Rubinstein

Mol Cancer Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Arjun Mittra, Geraldine H O' Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Lawrence Rubinstein

Cancer Chemother Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trametinib in Patients With , , or -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
Kari B Wisinski, Yael Flamand, Melissa A Wilson, Jason J Luke, Hussein A Tawbi, Lawrence V Rubinstein

JCO Precis Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
Alice P Chen, Shivaani Kummar, Nancy Moore, Lawrence V Rubinstein, Yingdong Zhao

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.
Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A Chow, Lawrence Rubinstein

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer.
Yeh Chen Lee, Lisa Wang, Elise C Kohn, Lawrence Rubinstein, S Percy Ivy

Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Tony Navas, Robert J Kinders, Scott M Lawrence, Katherine V Ferry-Galow, Suzanne Borgel, Lawrence Rubinstein

Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
Naoko Takebe, Jan H Beumer, Shivaani Kummar, Brian F Kiesel, Afshin Dowlati, Lawrence Rubinstein

Br J Clin Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials.
Channing J Paller, Erich P Huang, Thomas Luechtefeld, Holly A Massett, Christopher C Williams, Lawrence Rubinstein

Front Med (Lausanne)· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.
Andrew D Seidman, Louise Bordeleau, Louis Fehrenbacher, William E Barlow, Jane Perlmutter, Lawrence Rubinstein

J Clin Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?
Katherine V Ferry-Galow, Vivekananda Datta, Hala R Makhlouf, John Wright, Bradford J Wood, Lawrence V Rubinstein

J Oncol Pract· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data.
Jo Anne Zujewski, Lawrence Rubinstein

NPJ Breast Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
Patricia M LoRusso, Jing Li, Angelika Burger, Lance K Heilbrun, Edward A Sausville, Lawrence Rubinstein

Clin Cancer Res· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creating clinical trial designs that incorporate clinical outcome assessments.
Mark R Gilbert, Lawrence Rubinstein, Glenn Lesser

Neuro Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.
Chih-Jian Lih, David J Sims, Robin D Harrington, Eric C Polley, Yingdong Zhao, Lawrence V Rubinstein

J Mol Diagn· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials.
Yingdong Zhao, Eric C Polley, Ming-Chung Li, Chih-Jian Lih, Alida Palmisano, Lawrence V Rubinstein

Cancer Inform· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.
Philip A Philip, Kari Chansky, Michael LeBlanc, Lawrence Rubinstein, Lesley Seymour

Clin Cancer Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Jason J Luke, Lawrence V Rubinstein, Gary L Smith, S Percy Ivy, Pamela J Harris

Melanoma Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More randomization in phase II trials: necessary but not sufficient.
Lawrence Rubinstein, Michael Leblanc, Malcolm A Smith

J Natl Cancer Inst· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line therapy in ovarian cancer trials.
Tate Thigpen, Andreas duBois, Jessica McAlpine, Philip DiSaia, Keiichi Fujiwara, Lawrence Rubinstein

Int J Gynecol Cancer· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical trials in recurrent ovarian cancer.
Michael Friedlander, Edward Trimble, Anna Tinker, David Alberts, Elisabeth Avall-Lundqvist, Lawrence Rubinstein

Int J Gynecol Cancer· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
Lori E Dodd, Edward L Korn, Boris Freidlin, C Carl Jaffe, Lawrence V Rubinstein

J Clin Oncol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis